Published in Annu Rev Med on January 01, 2006
CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med (2006) 3.57
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis (2007) 3.02
CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis (2010) 2.72
Crystal structure of the West Nile virus envelope glycoprotein. J Virol (2006) 2.61
Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. J Virol (2006) 2.20
Infectious disease in a warming world: how weather influenced West Nile virus in the United States (2001-2005). Environ Health Perspect (2009) 1.96
West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A (2006) 1.83
Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog (2009) 1.81
Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. J Immunol (2010) 1.58
West Nile virus and its emergence in the United States of America. Vet Res (2010) 1.56
West Nile virus infection of Drosophila melanogaster induces a protective RNAi response. Virology (2008) 1.56
Association of West Nile virus illness and urban landscapes in Chicago and Detroit. Int J Health Geogr (2007) 1.55
A novel system for the launch of alphavirus RNA synthesis reveals a role for the Imd pathway in arthropod antiviral response. PLoS Pathog (2009) 1.53
West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: Transmigration across the in vitro blood-brain barrier. Virology (2009) 1.49
Differential activation of human monocyte-derived and plasmacytoid dendritic cells by West Nile virus generated in different host cells. J Virol (2007) 1.48
Current status of veterinary vaccines. Clin Microbiol Rev (2007) 1.44
A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis (2011) 1.42
Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. J Virol (2007) 1.38
Genetic diversity and purifying selection in West Nile virus populations are maintained during host switching. Virology (2008) 1.29
Reversal of West Nile virus-induced blood-brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor. Virology (2009) 1.25
West Nile virus meningoencephalitis. Nat Clin Pract Neurol (2006) 1.22
West Nile virus-induced disruption of the blood-brain barrier in mice is characterized by the degradation of the junctional complex proteins and increase in multiple matrix metalloproteinases. J Gen Virol (2012) 1.21
Genetic variability of West Nile virus in US blood donors, 2002-2005. Emerg Infect Dis (2008) 1.21
Evolution of new genotype of West Nile virus in North America. Emerg Infect Dis (2011) 1.20
A framework for evaluating animals as sentinels for infectious disease surveillance. J R Soc Interface (2007) 1.18
West Nile virus infection among humans, Texas, USA, 2002-2011. Emerg Infect Dis (2013) 1.14
Incubation periods of mosquito-borne viral infections: a systematic review. Am J Trop Med Hyg (2014) 1.14
Noncoding subgenomic flavivirus RNA: multiple functions in West Nile virus pathogenesis and modulation of host responses. Viruses (2014) 1.13
Epitope-blocking enzyme-linked immunosorbent assay to differentiate west nile virus from Japanese encephalitis virus infections in equine sera. Clin Vaccine Immunol (2007) 1.13
Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis (2009) 1.11
Inflammasome adaptor protein Apoptosis-associated speck-like protein containing CARD (ASC) is critical for the immune response and survival in west Nile virus encephalitis. J Virol (2013) 1.10
Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors. PLoS One (2007) 1.09
Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses. Clin Exp Vaccine Res (2013) 1.07
Clinical manifestations and outcomes of West Nile virus infection. Viruses (2014) 1.05
Evolutionary dynamics of West Nile virus in the United States, 1999-2011: phylogeny, selection pressure and evolutionary time-scale analysis. PLoS Negl Trop Dis (2013) 1.05
Serologic surveillance for West Nile virus and other flaviviruses in febrile patients, encephalitic patients, and asymptomatic blood donors in northern Mexico. Vector Borne Zoonotic Dis (2010) 1.03
Discovery of a non-peptidic inhibitor of west nile virus NS3 protease by high-throughput docking. PLoS Negl Trop Dis (2009) 1.01
Rapid GIS-based profiling of West Nile virus transmission: defining environmental factors associated with an urban-suburban outbreak in Northeast Ohio, USA. Geospat Health (2008) 1.00
Climate change impacts on West Nile virus transmission in a global context. Philos Trans R Soc Lond B Biol Sci (2015) 1.00
Predictive mapping of human risk for West Nile virus (WNV) based on environmental and socioeconomic factors. PLoS One (2011) 0.99
Differential virulence and pathogenesis of West Nile viruses. Viruses (2013) 0.99
Association between HLA class I and class II alleles and the outcome of West Nile virus infection: an exploratory study. PLoS One (2011) 0.98
Role of two distinct gammadelta T cell subsets during West Nile virus infection. FEMS Immunol Med Microbiol (2008) 0.97
Continued evolution of West Nile virus, Houston, Texas, USA, 2002-2012. Emerg Infect Dis (2013) 0.96
Mechanism of West Nile virus neuroinvasion: a critical appraisal. Viruses (2014) 0.96
Impaired virus clearance, compromised immune response and increased mortality in type 2 diabetic mice infected with West Nile virus. PLoS One (2012) 0.96
In vitro effects of selenium deficiency on West Nile virus replication and cytopathogenicity. Virol J (2008) 0.95
Chemokine control of West Nile virus infection. Exp Cell Res (2011) 0.95
Current trends in West Nile virus vaccine development. Expert Rev Vaccines (2014) 0.93
West nile virus attenuates activation of primary human macrophages. Viral Immunol (2008) 0.92
First international diagnostic accuracy study for the serological detection of West Nile virus infection. BMC Infect Dis (2007) 0.91
HTS-driven discovery of new chemotypes with West Nile Virus inhibitory activity. Molecules (2010) 0.91
Terrestrial vegetation and aquatic chemistry influence larval mosquito abundance in catch basins, Chicago, USA. Parasit Vectors (2013) 0.90
Transmission of West Nile virus during horse autopsy. Emerg Infect Dis (2010) 0.90
Identification of CD8+ T cell epitopes in the West Nile virus polyprotein by reverse-immunology using NetCTL. PLoS One (2010) 0.89
The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers. Vaccine (2013) 0.89
Oral administration of active hexose correlated compound enhances host resistance to West Nile encephalitis in mice. J Nutr (2009) 0.89
West Nile virus infection in American Robins: new insights on dose response. PLoS One (2013) 0.88
Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses. Clin Vaccine Immunol (2007) 0.88
Genetic analysis of West Nile virus isolates from an outbreak in Idaho, United States, 2006-2007. Int J Environ Res Public Health (2013) 0.87
Community-acquired meningitis in older adults: clinical features, etiology, and prognostic factors. J Am Geriatr Soc (2014) 0.87
The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states. J Virol (2013) 0.86
Role of natural killer and Gamma-delta T cells in West Nile virus infection. Viruses (2013) 0.86
West Nile virus neuroinvasive disease: neurological manifestations and prospective longitudinal outcomes. BMC Infect Dis (2014) 0.86
Identification of multiple RIG-I-specific pathogen associated molecular patterns within the West Nile virus genome and antigenome. Virology (2012) 0.84
An analogue of AICAR with dual inhibitory activity against WNV and HCV NTPase/helicase: synthesis and in vitro screening of 4-carbamoyl-5-(4,6-diamino-2,5-dihydro-1,3,5-triazin-2-yl)imidazole-1-beta-D-ribofuranoside. Bioorg Med Chem Lett (2007) 0.84
A review of vaccine approaches for West Nile virus. Int J Environ Res Public Health (2013) 0.83
Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol (2014) 0.82
Reduced immune cell infiltration and increased pro-inflammatory mediators in the brain of Type 2 diabetic mouse model infected with West Nile virus. J Neuroinflammation (2014) 0.82
Identification of blood meal sources in Aedes vexans and Culex quinquefasciatus in Bernalillo County, New Mexico. J Insect Sci (2013) 0.81
West nile virus. Transfus Med Hemother (2013) 0.81
Evaluation of a rapid analyte measurement platform for West Nile virus detection based on United States mosquito control programs. Am J Trop Med Hyg (2012) 0.81
Fatal neurologic disease and abortion in mare infected with lineage 1 West Nile virus, South Africa. Emerg Infect Dis (2011) 0.81
Flavitrack analysis of the structure and function of West Nile non-structural proteins. Int J Bioinform Res Appl (2010) 0.80
A single amino acid substitution in the core protein of West Nile virus increases resistance to acidotropic compounds. PLoS One (2013) 0.80
Evaluation of an epitope-blocking enzyme-linked immunosorbent assay for the diagnosis of West Nile virus infections in humans. Clin Vaccine Immunol (2009) 0.80
Comparison of the neuropathology induced by two West Nile virus strains. PLoS One (2013) 0.80
Reverse ELISA for the detection of anti West Nile virus IgG antibodies in humans. Eur J Clin Microbiol Infect Dis (2007) 0.80
Close relationship between West Nile virus from Turkey and lineage 1 strain from Central African Republic. Emerg Infect Dis (2015) 0.80
Infection with non-lethal West Nile virus Eg101 strain induces immunity that protects mice against the lethal West Nile virus NY99 strain. Viruses (2014) 0.79
Deciphering the molecular basis for nucleotide selection by the West Nile virus RNA helicase. Nucleic Acids Res (2010) 0.79
Vector competence of northern European Culex pipiens biotypes and hybrids for West Nile virus is differentially affected by temperature. Parasit Vectors (2016) 0.79
Induction of virus-specific effector immune cell response limits virus replication and severe disease in mice infected with non-lethal West Nile virus Eg101 strain. J Neuroinflammation (2015) 0.79
Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis. J Gen Virol (2015) 0.79
Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. PLoS One (2014) 0.79
Neuroinvasive West Nile Infection Elicits Elevated and Atypically Polarized T Cell Responses That Promote a Pathogenic Outcome. PLoS Pathog (2016) 0.78
The expression of the chemokine receptor CCR5 in tick-borne encephalitis. J Neuroinflammation (2016) 0.78
Amino acid substitutions in the non-structural proteins 4A or 4B modulate the induction of autophagy in West Nile virus infected cells independently of the activation of the unfolded protein response. Front Microbiol (2015) 0.78
Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge. Immunology (2010) 0.78
Identification of host genes leading to West Nile virus encephalitis in mice brain using RNA-seq analysis. Sci Rep (2016) 0.77
Differences in Early Cytokine Production Are Associated With Development of a Greater Number of Symptoms Following West Nile Virus Infection. J Infect Dis (2016) 0.76
Impact of viral attachment factor expression on antibody-mediated neutralization of flaviviruses. Virology (2013) 0.76
Perspectives of public health laboratories in emerging infectious diseases. Emerg Microbes Infect (2013) 0.76
T cell epitope mapping of the e-protein of West Nile virus in BALB/c mice. PLoS One (2014) 0.76
Relating West Nile virus case fatality rates to demographic and surveillance variables. Public Health Rep (2007) 0.75
Review of West Nile virus circulation and outbreak risk in Madagascar: Entomological and ornithological perspectives. Parasite (2016) 0.75
A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers. J Infect Dis (2016) 0.75
Visual Detection of West Nile Virus Using Reverse Transcription Loop-Mediated Isothermal Amplification Combined with a Vertical Flow Visualization Strip. Front Microbiol (2016) 0.75
Extrinsic Incubation Rate is Not Accelerated in Recent California Strains of West Nile Virus in Culex tarsalis (Diptera: Culicidae). J Med Entomol (2015) 0.75
Dengue: a continuing global threat. Nat Rev Microbiol (2010) 9.96
Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med (2004) 8.54
West Nile virus. Lancet Infect Dis (2002) 7.97
Dengue prevention and 35 years of vector control in Singapore. Emerg Infect Dis (2006) 4.55
Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis (2003) 4.29
Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission. PLoS Negl Trop Dis (2010) 4.10
Dengue fever, Hawaii, 2001-2002. Emerg Infect Dis (2005) 3.62
Selection-driven evolution of emergent dengue virus. Mol Biol Evol (2003) 3.27
Evaluation of diagnostic tests: dengue. Nat Rev Microbiol (2010) 2.91
Geographic expansion of dengue: the impact of international travel. Med Clin North Am (2008) 2.91
West Nile virus. JAMA (2003) 2.76
Development of real-time reverse transcriptase PCR assays to detect and serotype dengue viruses. J Clin Microbiol (2006) 2.45
The economic burden of dengue. Am J Trop Med Hyg (2012) 2.31
Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis (2009) 2.26
Serologic evidence of West Nile virus infection in horses, Coahuila State, Mexico. Emerg Infect Dis (2003) 2.26
Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic dengue hemorrhagic fever. Am J Trop Med Hyg (2002) 2.26
Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention. Cad Saude Publica (2009) 2.22
Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr Infect Dis Rep (2010) 2.14
Molecular evolution of dengue 2 virus in Puerto Rico: positive selection in the viral envelope accompanies clade reintroduction. J Gen Virol (2006) 2.07
Serologic evidence of West Nile virus infection in horses, Yucatan State, Mexico. Emerg Infect Dis (2003) 1.99
Seroprevalence and distribution of Flaviviridae, Togaviridae, and Bunyaviridae arboviral infections in rural Cameroonian adults. Am J Trop Med Hyg (2006) 1.87
Cost-effectiveness of a pediatric dengue vaccine. Vaccine (2004) 1.83
West Nile virus detection in urine. Emerg Infect Dis (2005) 1.76
Chikungunya and dengue fever among hospitalized febrile patients in northern Tanzania. Am J Trop Med Hyg (2012) 1.68
West Nile virus transmission in resident birds, Dominican Republic. Emerg Infect Dis (2003) 1.59
Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol (2003) 1.55
Cities spawn epidemic dengue viruses. Nat Med (2004) 1.54
Community-based dengue prevention programs in Puerto Rico: impact on knowledge, behavior, and residential mosquito infestation. Am J Trop Med Hyg (2002) 1.53
Natural attenuation of dengue virus type-2 after a series of island outbreaks: a retrospective phylogenetic study of events in the South Pacific three decades ago. Virology (2010) 1.53
Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology (2003) 1.50
Serologic survey of domestic animals for zoonotic arbovirus infections in the Lacandón Forest region of Chiapas, Mexico. Vector Borne Zoonotic Dis (2003) 1.50
A method for full genome sequencing of all four serotypes of the dengue virus. J Virol Methods (2010) 1.48
Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep (2002) 1.48
Dengue in Grenada. Rev Panam Salud Publica (2005) 1.45
Longitudinal studies of West Nile virus infection in avians, Yucatán State, México. Vector Borne Zoonotic Dis (2004) 1.45
Disease ecology and the global emergence of zoonotic pathogens. Environ Health Prev Med (2005) 1.26
New dengue virus type 1 genotype in Colombo, Sri Lanka. Emerg Infect Dis (2011) 1.17
Serologic evidence of West Nile Virus infection in birds, Tamaulipas State, México. Vector Borne Zoonotic Dis (2003) 1.14
Risk factors for infection during a dengue-1 outbreak in Maui, Hawaii, 2001. Trans R Soc Trop Med Hyg (2005) 1.11
An explosive epidemic of DENV-3 in Cairns, Australia. PLoS One (2013) 1.08
Emergence and diversification of dengue 2 cosmopolitan genotype in Pakistan, 2011. PLoS One (2013) 1.06
Exploring the origin and potential for spread of the 2013 dengue outbreak in Luanda, Angola. Glob Health Action (2013) 1.05
Emerging vector-borne flavivirus diseases: are vaccines the solution? Expert Rev Vaccines (2011) 1.04
Guidelines on the cost-effectiveness of larval control programs to reduce dengue transmission in Puerto Rico. Rev Panam Salud Publica (2003) 0.95
Comparison of the mosquito inoculation technique and quantitative real time polymerase chain reaction to measure dengue virus concentration. Am J Trop Med Hyg (2013) 0.94
Environmental health implications of global climate change. J Environ Monit (2005) 0.91
Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis. Nat Rev Microbiol (2013) 0.91
Assessment of dengue risk in relief workers in Puerto Rico after Hurricane Georges, 1998. Am J Trop Med Hyg (2002) 0.88
Scrub typhus with sepsis and acute respiratory distress syndrome. J Clin Microbiol (2013) 0.88
Unfolded protein response (UPR) gene expression during antibody-dependent enhanced infection of cultured monocytes correlates with dengue disease severity. Biosci Rep (2011) 0.85
Japanese encephalitis: the need for a more effective vaccine. Lancet (2005) 0.83
Genetic variation within the premembrane coding region of dengue viruses from the Yucatan peninsula of Mexico. Am J Trop Med Hyg (2002) 0.81
Chikungunya as a cause of acute febrile illness in southern Sri Lanka. PLoS One (2013) 0.79
Isolation and titration of dengue viruses by the mosquito inoculation technique. Methods Mol Biol (2014) 0.79
The 20th century re-emergence of epidemic infectious diseases: lessons learned and future prospects. Med J Aust (2012) 0.75